NASDAQ:VTAE - Vitae Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$21.00 0.00 (0.00 %)
(As of 11/19/2018 06:16 AM ET)
Previous Close$21.00
Today's Range$21.00 - $21.00
52-Week Range$4.08 - $21.03
VolumeN/A
Average Volume763,870 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Receive VTAE News and Ratings via Email

Sign-up to receive the latest news and ratings for VTAE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:VTAE
Previous Symbol
CUSIPN/A
Phone+1-215-4612000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees56
Outstanding SharesN/A
Market Cap$0.00
OptionableNot Optionable

Vitae Pharmaceuticals (NASDAQ:VTAE) Frequently Asked Questions

What is Vitae Pharmaceuticals' stock symbol?

Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."

Has Vitae Pharmaceuticals been receiving favorable news coverage?

News stories about VTAE stock have trended positive on Monday, according to InfoTrie. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vitae Pharmaceuticals earned a media sentiment score of 2.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 3.0 out of 10, meaning that recent news coverage is unlikely to have an effect on the company's share price in the immediate future.

How do I buy shares of Vitae Pharmaceuticals?

Shares of VTAE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vitae Pharmaceuticals' stock price today?

One share of VTAE stock can currently be purchased for approximately $21.00.

What is Vitae Pharmaceuticals' official website?

The official website for Vitae Pharmaceuticals is http://ir.vitaepharma.com/phoenix.zhtml.

How can I contact Vitae Pharmaceuticals?

Vitae Pharmaceuticals' mailing address is 502 W Office Center Dr, FORT WASHINGTON, PA 19034-3215, United States. The biotechnology company can be reached via phone at +1-215-4612000.


MarketBeat Community Rating for Vitae Pharmaceuticals (NASDAQ VTAE)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  105 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Vitae Pharmaceuticals and other stocks. Vote "Outperform" if you believe VTAE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTAE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel